BOCA RATON, Fla., Sept. 15, 2023 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., FWBI, (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, President and CEO, will make a company presentation at the…Read More
First Wave BioPharma To Present at the BIO Investor Forum First Wave BioPharma NASDAQFWBI
